Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,370Revenue $M443Net Margin (%)55.4Z-Score4.1
Enterprise Value $M1,661EPS $1.7Operating Margin %91.2F-Score3
P/E(ttm))5.1Cash Flow Per Share $1.5Pre-tax Margin (%)87.3Higher ROA y-yN
Price/Book4.610-y EBITDA Growth Rate %0Quick Ratio0.8Cash flow > EarningsN
Price/Sales2.85-y EBITDA Growth Rate %20.0Current Ratio0.8Lower Leverage y-yY
Price/Cash Flow5.0y-y EBITDA Growth Rate %8.2ROA % (ttm)44.9Higher Current Ratio y-yN
Dividend Yield %7.1Insider Buy (3m)0ROE % (ttm)213Less Shares Outstanding y-yN
Payout Ratio %36.0Shares Outstanding M161ROI % (ttm)162Gross Margin Increase y-yN

Gurus Latest Trades with PDLI

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
PDLIJohn Hussman 2014-06-30 Sold Out -0.68%$8 - $9.85
($8.9)
$ 8.53-4%Sold Out0
PDLIJoel Greenblatt 2014-06-30 Reduce-0.11%$8 - $9.85
($8.9)
$ 8.53-4%Reduce -52.58%789,804
PDLIJoel Greenblatt 2014-03-31 Reduce-0.34%$7.46 - $9.14
($8.57)
$ 8.530%Reduce -50.19%1,665,543
PDLIJohn Hussman 2013-12-31 Reduce-0.49%$7.59 - $10.1
($8.43)
$ 8.531%Reduce -50.99%1,087,000
PDLIJoel Greenblatt 2013-09-30 Add0.15%$7.72 - $8.44
($8.04)
$ 8.536%Add 24.84%2,890,564
PDLIJohn Hussman 2013-09-30 Reduce-0.21%$7.72 - $8.44
($8.04)
$ 8.536%Reduce -21.04%2,218,000
PDLIJoel Greenblatt 2013-03-31 Add0.15%$6.65 - $7.53
($7.08)
$ 8.5320%Add 23.5%2,135,460
PDLIJoel Greenblatt 2012-12-31 Add0.59%$7.09 - $8.37
($7.75)
$ 8.5310%Add 561.89%1,729,133
PDLIJohn Hussman 2012-12-31 Add0.09%$7.09 - $8.37
($7.75)
$ 8.5310%Add 20.19%3,012,000
PDLIJohn Hussman 2012-09-30 Add0.29%$6.59 - $7.73
($7.11)
$ 8.5320%Add 176.91%2,506,000
PDLIJoel Greenblatt 2012-03-31 Add0.04%$6.02 - $6.58
($5.93)
$ 8.5344%Add 33.54%270,346
PDLISeth Klarman 2012-03-31 Sold Out -1.5%$6.02 - $6.58
($5.93)
$ 8.5344%Sold Out0
PDLIJoel Greenblatt 2011-12-31 Add0.04%$5.35 - $6.4
($5.97)
$ 8.5343%Add 31.29%202,444
PDLISeth Klarman 2011-12-31 Reduce-1.4%$5.35 - $6.4
($5.97)
$ 8.5343%Reduce -48.84%8,000,000
PDLIGeorge Soros 2011-12-31 Sold Out -0.001%$5.35 - $6.4
($5.97)
$ 8.5343%Sold Out0
PDLISeth Klarman 2011-09-30 Add1.17%$5.47 - $6.39
($5.91)
$ 8.5344%Add 68.81%15,636,000
PDLIJohn Hussman 2011-09-30 Buy 0.08%$5.47 - $6.39
($5.91)
$ 8.5344%New holding, 905000 sh.905,000
PDLIJoel Greenblatt 2011-09-30 Add0.04%$5.47 - $6.39
($5.91)
$ 8.5344%Add 41.81%154,201
PDLIGeorge Soros 2011-09-30 Buy $5.47 - $6.39
($5.91)
$ 8.5344%New holding, 10000 sh.10,000
PDLIGeorge Soros 2011-06-30 Sold Out $5.74 - $6.64
($6.23)
$ 8.5337%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

PDLI is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
PDLI Jean-Marie Eveillard 2014-06-302,80000
PDLI Joel Greenblatt 2014-06-30789,8040.490.1-52.58%
PDLI John Hussman 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


PDLI: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Lindell Jody SDirector 2011-03-15Buy374$5.3358.91view
LARSON CHRISTINE RVice President and CFO 2010-05-14Buy5,000$5.7148.34view
LARSON CHRISTINE RVice President and CFO 2010-04-30Buy10,000$6.1837.06view
KLEIN JOSEPH IIIDirector 2009-11-04Sell24,000$8.331.68view
Lindell Jody SDirector 2009-06-15Buy3,000$7.769.15view
SANDMAN PAUL WDirector 2009-04-08Buy10,000$7.3814.77view
SANDMAN PAUL WDirector 2009-04-08Buy10,000$7.3814.77view
KLEIN JOSEPH IIIDirector 2008-05-20Buy500$9.5-10.84view
KLEIN JOSEPH IIIDirector 2008-05-06Buy500$9.6-11.77view
KLEIN JOSEPH IIIDirector 2008-04-21Buy500$13.87-38.93view

Press Releases about PDLI :

Quarterly/Annual Reports about PDLI:

News about PDLI:

Articles On GuruFocus.com
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against PDL BioPharma, Oct 17 2014 
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against PDL BioPharma Inc Oct 15 2014 
Hot Picks with High Yields Jul 23 2013 
My 3 Favorite Healthcare Dividend Stocks with Highest Float Short Ratio Jun 03 2013 
comment on PDLI May 12 2013 
My 4 Favorites From The 20 Cheapest Healthcare Dividend Stock List May 02 2013 
FV 22 MSN 10 Apr 19 2013 
68 Top-Yielding Stocks with Ex-Dividend Date in March 2013 Feb 27 2013 
20 Best Yielding Healthcare Growth Stocks and Which to Buy Feb 02 2013 
comment on PDLI Nov 13 2012 


More From Other Websites
INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the... Oct 28 2014
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against PDL BioPharma... Oct 27 2014
Biogen Falls on Concerns Regarding Tecfidera Sales and PML Case Oct 24 2014
Alexion Beats on Earnings & Revenues in Q3, Guides Up Oct 23 2014
Celgene Beats Q3 Earnings Estimates on High Revlimid Sales Oct 23 2014
Cubist Pharmaceuticals' Q3 Earnings Beat Expectations Oct 23 2014
PDL BIOPHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered... Oct 22 2014
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action against PDL BioPharma... Oct 21 2014
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against PDL BioPharma,... Oct 17 2014
SHAREHOLDER ALERT: Investigation on Behalf of PDL BioPharma, Inc. Investors Announced by Law Offices... Oct 17 2014
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From... Oct 15 2014
Deadline in Lawsuit for Investors in PDL BioPharma Inc (PDLI) Shares Announced by Shareholders... Oct 14 2014
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In PDL... Oct 10 2014
EQUITY ALERT: Rosen Law Firm Reminds PDL BioPharma, Inc. Investors of Important Class Action... Oct 10 2014
Weakness Seen in Galena Biopharma (GALE) Estimates: Should You Stay Away? Oct 09 2014
Emergent BioSolutions Revamps Business to Drive Earnings Oct 08 2014
PDL BIOPHARMA, INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Other Events,... Oct 08 2014
PDL Announces Appointment of PricewaterhouseCoopers LLP as its New Independent Registered Public... Oct 08 2014
Regeneron's Eye Drug Eylea Wins Another FDA Approval Oct 07 2014
Alnylam Begins New Study on Hepatic Porphyrias Patients Oct 06 2014

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK